With strong revenue growth projections, Mesoblast Limited (NASDAQ:MESO) secures a spot on our list of the best long-term ASX stocks to buy right now.
As of April 15, 2026, all covering analysts remain bullish on Mesoblast Limited (NASDAQ:MESO), with a consensus price target of $32.5, implying upside potential of 106.5%.
That positive sentiment is largely driven by Ryoncil’s growing clinical potential and expanding commercial opportunity.
On April 7, 2026, Mesoblast Limited (NASDAQ:MESO) announced that the FDA granted IND clearance to advance directly into a registration trial of Ryoncil for Duchenne muscular dystrophy, representing an important milestone in the context of the therapy’s potential market expansion beyond its existing approval for pediatric steroid-refractory acute graft-versus-host disease.
In addition to this, the upcoming study is expected to enroll 76 patients aged 5 to 9, with time-to-stand at nine months set as the primary endpoint. Management is also collaborating with Parent Project Muscular Dystrophy to aid patient identification and raise awareness of the trial, which should support execution.
That pipeline progress is also supported by early signs of commercial traction.
On April 6, 2026, Mesoblast Limited (NASDAQ:MESO) reported Ryoncil net sales of $30.3 million for the March quarter, with first-year launch revenue nearing $100 million. Management noted that these proceeds are strengthening the company’s balance sheet and helping finance label expansion efforts and late-stage clinical programs, further supporting the company’s long-term growth outlook.
Mesoblast Limited (NASDAQ:MESO), together with its subsidiaries, develops regenerative medicine products in Australia, the US, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
